Crescendo Biologics Ltd. (United Kingdom)
Crescendo Biologics announces that Zai Lab has initiated a global Phase 2 clinical trial evaluating ZL-1102 (Humabody®, CB001) as a topical treatment for psoriasis Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024 Crescendo Biologics announces first U.S.
Basic Information
- Category: business
- Website: https://www.crescendobiologics.com
Documented Facts
- Inception (Wikidata): 2007 (Source 3: Wikidata Q138860465, revision 2477621473)
- Country (Wikidata; date unspecified): United Kingdom (Source 3: Wikidata Q138860465, revision 2477621473; Source 4: Wikidata label: Q145, revision 2554939741)
- Official website (Wikidata; date unspecified): https://www.crescendobiologics.com/ (Source 3: Wikidata Q138860465, revision 2477621473)
Evidence and Sources
- Crescendo Biologics Ltd. (United Kingdom) — Official Site (official)
- Crescendo Biologics Ltd. (United Kingdom) on linkedin (social)
- Wikidata Q138860465, revision 2477621473 (knowledge-base)
- Wikidata label: Q145, revision 2554939741 (knowledge-base)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Crescendo Biologics Ltd. (United Kingdom).
- Canonical profile: https://brandsource.ai/brands/crescendo-biologics-ltd-united-kingdom
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/crescendo-biologics-ltd-united-kingdom/json-ld
- Citation profile API: https://brandsource.ai/api/brands/crescendo-biologics-ltd-united-kingdom/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Crescendo Biologics announces that Zai Lab has initiated a global Phase 2 clinical trial evaluating ZL-1102 (Humabody®, CB001) as a topical treatment for psoriasis Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024 Crescendo Biologics announces first U.S.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 3 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.